The Icahn School of Medicine at Mount Sinai (ISMMS) is led by Dean Dennis S. Charney, MD. Chartered in 1963, it is the sole medical school for the Mount Sinai Health System which comprises seven hospital campuses and numerous ambulatory centers. The Icahn School of Medicine has more than 5,000 faculty and nearly 2,000 students, residents and fellows.
Message from the Dean
Icahn School of Medicine at Mount Sinai is proud to be a national and international leader in biomedical education, research and patient care. Since its inception 50 years ago, Mount Sinai's renowned faculty, talented students and dedicated staff have risen to the challenges of our visionary founders to build an outstanding top-tier U.S. medical school.
"It is my goal to have Mount Sinai graduates remake the image of the American physician — one who is committed, selfless, and ethical, and at the same time, translational and transformative." Dennis S. Charney, MD
A culture of innovation and a passion for pushing the boundaries of knowledge are integral to all activities at Icahn School of Medicine at Mount Sinai, driving us on a daily basis to challenge existing limitations of science and medicine to create and discover what was previously thought to be impossible. A $2.25 billion strategic plan emphasizing translational medicine provides both a roadmap and resources for the School's efforts. The magnificent new 550,000-square-foot Leon and Norma Hess Center for Science and Medicine places scientists and physicians in close proximity that fosters cross-fertilization of ideas, stimulates progress and encourages creativity and entrepreneurship. Throughout Mount Sinai, intensive collaboration across our 34 academic departments and 22 multidisciplinary institutes facilitates discoveries running from the laboratory through to patient care.
Ranked 17 among U.S. medical schools for National Institutes of Health funding, Icahn School of Medicine at Mount Sinai faculty are securing unprecedented levels of extramural funding for their research, and grant dollars per investigator are among the highest in the country. The robust infrastructure supporting scientific advances includes major investments by Mount Sinai in genomics, high performance computing, computational biology, molecular pathology and imaging to enhance our ability to predict, diagnose, treat and prevent human disease.
Read more from Dr. Charney, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai and President for Academic Affairs, Mount Sinai Health System.